Global M&A Intelligence Report 2023 – Life Sciences Supplement
An analysis of the trends, challenges and opportunities in the global life sciences M&A marketThis report provides an insight into life sciences M&A deal activity in 2022 and supplements our 2023 global M&A intelligence report, which is now in its ninth edition.
The life sciences sector is broad and captures a number of sub-sectors, including pharmaceutical, medical devices and biotech.
The report looks at a selection of our international corporate life sciences transactions to identify trends and developments, which can provide insightful intelligence for those operating in the sector and considering M&A activity, both domestically or internationally.
The report focuses on five key themes:
- Due Diligence (DD)
- Warranty and Indemnity (W&I) insurance
- Transaction structures
- Trade v Private Equity
- US v Rest of the World (RoW)
“Buyers and investors must pay close attention in conducting adequate regulatory due diligence, when evaluating targets in rapidly evolving environments.”
Please note, requests will be reviewed and approved at the discretion of DLA Piper. We cannot guarantee you will receive the report after submitting a request. Alternatively, please get in touch with your usual DLA Piper contact to request a copy.
